Merck & Co Inc
NYSE:MRK

Watchlist Manager
Merck & Co Inc Logo
Merck & Co Inc
NYSE:MRK
Watchlist
Price: 99.18 USD -0.68% Market Closed
Market Cap: 250.9B USD
Have any thoughts about
Merck & Co Inc?
Write Note

Merck & Co Inc
Other Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Merck & Co Inc
Other Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Assets CAGR 3Y CAGR 5Y CAGR 10Y
Merck & Co Inc
NYSE:MRK
Other Assets
$21.7B
CAGR 3-Years
5%
CAGR 5-Years
2%
CAGR 10-Years
5%
Johnson & Johnson
NYSE:JNJ
Other Assets
$44.8B
CAGR 3-Years
8%
CAGR 5-Years
6%
CAGR 10-Years
8%
Bristol-Myers Squibb Co
NYSE:BMY
Other Assets
$21.8B
CAGR 3-Years
2%
CAGR 5-Years
27%
CAGR 10-Years
12%
Pfizer Inc
NYSE:PFE
Other Assets
$68.4B
CAGR 3-Years
11%
CAGR 5-Years
3%
CAGR 10-Years
5%
Zoetis Inc
NYSE:ZTS
Other Assets
$2.7B
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
11%
Eli Lilly and Co
NYSE:LLY
Other Assets
$5.8B
CAGR 3-Years
14%
CAGR 5-Years
9%
CAGR 10-Years
N/A
No Stocks Found

Merck & Co Inc
Glance View

Market Cap
251.1B USD
Industry
Pharmaceuticals

Merck & Co., Inc., a global leader in the pharmaceutical industry, has been on a transformative journey that reflects its commitment to innovation and improving health outcomes around the world. Founded in 1891, the company has grown into a powerhouse known for its diverse product portfolio, which includes groundbreaking vaccines, oncology therapies, and treatments for chronic diseases. With a rich history of fostering research and development, Merck invests heavily in scientific advancements, positioning itself at the forefront of medical breakthroughs. This dedication has led to the successful launch of key products, such as the human papillomavirus (HPV) vaccine Gardasil and the cancer immunotherapy Keytruda, which has gained significant traction and revenue, making it one of the top-selling drugs globally. As an investor, understanding Merck's strategic direction is crucial. The company is not only focused on maintaining its legacy in pharmaceuticals but also on expanding its presence in biopharma through collaborations and acquisitions, enhancing its pipeline of potential therapies. With a robust dividend history, Merck has demonstrated its commitment to returning value to shareholders, signifying financial stability and confidence in ongoing business fundamentals. Furthermore, as the global demand for innovative health solutions accelerates, Merck's proactive approach to addressing emerging health challenges positions it for sustainable growth. For investors, the combination of Merck’s rich heritage, innovative spirit, and sound financial practices creates an appealing narrative that carries potential for long-term returns.

MRK Intrinsic Value
136.99 USD
Undervaluation 28%
Intrinsic Value
Price

See Also

What is Merck & Co Inc's Other Assets?
Other Assets
21.7B USD

Based on the financial report for Sep 30, 2024, Merck & Co Inc's Other Assets amounts to 21.7B USD.

What is Merck & Co Inc's Other Assets growth rate?
Other Assets CAGR 10Y
5%

Over the last year, the Other Assets growth was 2%. The average annual Other Assets growth rates for Merck & Co Inc have been 5% over the past three years , 2% over the past five years , and 5% over the past ten years .

Back to Top